Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
  • C07D277/62—Benzothiazoles
  • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/02—Nasal agents, e.g. decongestants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/06—Antiasthmatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
  • A61P11/08—Bronchodilators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
  • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention relates to benzothiazolone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
• Adrenoceptors are a group of G-protein coupled receptors divided into two major subfamilies, ⁇ and ⁇ . These sub-families are further divided into sub-types of which the ⁇ sub- family has at least 3 members: ⁇ l, ⁇ 2 and ⁇ 3. ⁇ 2 adrenoceptors (henceforth referred to as ⁇ 2 receptors) are mainly expressed on smooth muscle cells.
• ⁇ 2 agonists act as functional antagonists to all bronchoconstrictor substances such as the naturally-occurring histamine and acetylcholine as well as the experimental substances methacholine and carbachol.
• ⁇ 2 agonists are widely used to treat airways diseases including asthma and chronic obstructive pulmonary disease (COPD), and this has been extensively reviewed in the literature and incorporated into national guidelines for the treatment of these diseases (British Guideline on the Management of Asthma, NICE guideline No. 12 on the Management of COPD).
• ⁇ 2 agonists are classed either as short-acting or long-acting.
• Short-acting ⁇ 2 agonists such as salbutamol have a duration of action of 2-4 hours. They are suitable for rescue medication during a period of acute bronchoconstriction but are not suitable for continuous medication because the beneficial effect of these drugs wears off during the night.
• Long-acting ⁇ 2 agonists currently have a duration of action of about 12 hours and are administered twice daily to provide continuous bronchodilatation. They are particularly effective when administered in combination with inhaled corticosteroids. This benefit is not seen when inhaled corticosteroids are combined with SABAs (Kips and Pauwels, Am. J. Respir. Crit.
• LABAs are recommended as add-on therapy to patients already receiving inhaled corticosteroids for asthma to reduce nocturnal awakening and reduce the incidence of exacerbations of the disease.
• Corticosteroids and LABAs are conveniently co-administered in a single inhaler to improve patient compliance.
• Salmeterol a commonly used LABA
• Salmeterol also has a long onset of action which precludes its use as both a rescue and a maintenance therapy.
• All current LABAs are administered twice daily and there is a medical need for once daily treatments to improve treatment and patient compliance. Such once daily compounds, co-administered with corticosteroids, will become the mainstay of asthma treatment (Barnes, Nature Reviews, 2004, 3_, 831-844).
• Benzothiazolone derivatives having dual ⁇ 2 receptor and dopamine (D2) receptor agonist properties are known from WO 92/08708, WO 93/23385 and WO 97/10227.
• R 1 represents hydrogen; each of R 2 , R 3 , R 4 , R 5 , R 4' and R 5' independently represents hydrogen or C 1 -C 6 alkyl; e is O or l;
• A represents CH 2 , C(O) or S(O) 2 ;
• D represents oxygen, sulphur or NR 8 ; m is an integer from O to 3 ; n is an integer from O to 3;
• R 6 represents a group -(X) p -Y-(Z) q -R 10 ;
• X and Z each independently represent a C 1 -C 6 alkylene group optionally substituted by halogen, trifluoromethyl, amino (NH 2 ), ⁇ i)-C 1 -C 6 alkylamino, (di)-Cj-C6 alkylaminocarbonyl, C 1 -C 6 alkylcarbonylamino, sulphonamido (-SO 2 NH 2 ) or (di)-Ci-C 6 alkylaminosulphonyl; p and q each independently represent O or 1;
• Y represents a bond, oxygen, sulphur, CH 2 , C(O) or NR 9 ; provided that when p is O Y is not sulphur; R and R are, independently, hydrogen or C 1 -C 6 alkyl;
• R represents hydrogen or C 1 -C 6 alkyl
• R 9 represents hydrogen or Ci-C 6 alkyl
• R 10 represents hydrogen, or a saturated or unsaturated 3- to 10-membered ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by halogen, trifluoromethyl, cyano, carboxyl, hydroxyl, nitro, -S(O) 1 R 15 , -NR 16 S(O) 2 R 17 , -C(O)NR 18 R 19 , -NHC(O)R 20 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxycarbonyl or a saturated or unsaturated 4- to 7-membered monocyclic ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the monocyclic ring system itself being optionally substituted by halogen, trifluoromethyl, hydroxyl, -NR 21 S(O) 2 R 22
• R 16 , R 18 , R 19 , R 20 , R 21 and R 23 each independently represent hydrogen or C 1 -C 6 alkyl
• R 15 , R 17 and R 22 each independently represent C 1 -C 6 alkyl; r is 0, 1 or 2; R 7 represents a 5- to 14-membered aromatic or heteroaromatic ring system which is optionally substituted by halogen, trifluoromethyl, hydroxyl, carboxyl, C 1 -C 6 alkyl (optionally substituted by -NR 24 R 25 ), C 1 -C 6 alkoxy (optionally substituted by -NR 26 R 27 ), Ci-C 6 alkoxycarbonyl, -NR 28 R 29 , CpC 6 alkylcarbonylamino, Cj-C 6 alkylsulphonylamino, phenylsulphonylamino, -C(O)NHR 30 , -SO 2 NHR 33 , C 0 -C 6 alkyl-R 34 , or a phenyl or 5- or 6-membered heteroaromatic ring (each of which is optionally substituted by halogen, triflu
• R 30 represents hydrogen, Ci-C 6 alkyl, phenyl-Co-C 6 alkyl or C 2 -C 6 alkylene- NR 31 R 32 ; either R 31 and R 32 each independently represent hydrogen or Ci-C 6 alkyl, or R 31 and R 32 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen;
• R represents hydrogen, C 1 -C 6 alkyl, phenyl-Co-Ce alkyl or C 2 -C 6 alkylene- NR 37 R 38 ;
• R 34 represents a saturated, 5- or 6-membered nitrogen-containing ring
• R 35 and R 36 each independently represent hydrogen or C 1 -C 6 alkyl
• R 37 and R 38 each independently represent hydrogen or C 1 -C 6 alkyl, or R 37 and
• R together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen; with the proviso that R 6 does not represent hydrogen or an unsubstituted C 1 -C 6 alkyl group; or a pharmaceutically acceptable salt thereof.
• an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched.
• Examples of C 1 -C 6 alkyl groups/moieties include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyL tert-butyl, n-pentyl and n-hexyl.
• an alkylene group may be linear or branched.
• Examples OfC 1 -C 6 alkylene groups include methylene, ethylene, n-propylene, n-butylene, n-pentylene, n-hexylene, 1-methylethylene, 2-methylethylene, 1,2-dimethylethylene, 1-ethylethylene, 2-ethylethylene, 1-, 2- or 3-methylpropylene and 1-, 2- or 3- ethylpropylene.
• the alkyl moieties in a di-CpC ⁇ alkylamino, di-Q-C ⁇ alkylaminocarbonyl or di-Ci-C 6 alkylaminosulphonyl substituent group may be the same or different.
• the saturated or unsaturated 3- to 10-membered ring system and the saturated or unsaturated 4- to 7-membered monocyclic ring system may each have alicyclic or aromatic properties.
• An unsaturated ring system will be partially or fully unsaturated.
• R 31 and R 32 (or R 37 and R 38 ) together represent a 4- to 6-membered saturated heterocyclic ring it should be understood that the ring will contain no more than two ring heteroatoms: the nitrogen ring atom to which R 31 and R 32 (or R 37 and R 38 ) are attached and optionally a nitrogen or oxygen ring atom.
• the compounds of the invention are selective ⁇ 2 receptor agonists and possess properties that make them more suitable for once-a-day administration.
• Compounds have been optimised to have appropriate duration in an in vitro guinea pig trachea model, or mammalian model such as a histamine-challenged guinea pig.
• the compounds also have advantageous pharmokinetic half lives in mammalian systems.
• the compounds of the invention are at least 10-fold more potent at the ⁇ 2 receptor compared to the ⁇ l, ⁇ l, or dopamine (D2) receptors.
• the compounds are also notable for having a fast onset of action that is the time interval between administration of a compound of the invention to a patient and the compound providing symptomatic relief. Onset can be predicted in vitro using isolated trachea from guinea pig or human.
• the present invention provides a compound of formula (I) wherein R 1 represents hydrogen; each of R 2 , R 3 , R 4 , R 5 , R 4 and R 5 independently represents hydrogen or C 1 -C 6 alkyl; e is O or 1;
• A represents CH 2 , C(O) or S(O) 2 ;
• D represents oxygen, sulphur or NR 8 ;
• m is an integer from 0 to 3;
• n is an integer from 0 to 3;
• R 6 represents a group -(X) p -Y-(Z) q -R 10 ;
• X and Z each independently represent a C 1 -C 6 alkylene group optionally substituted with at least one substituent selected from halogen, trifluoromethyl, amino (NH 2 ), (di)- C 1 -C 6 alkylamino, ⁇ i)-C 1 -C 6 alkylaminocarbonyl, C 1 -C 6 alkylcarbonylamino, sulphonamido (-SO 2 NH 2 ) and (dO-Q-C ⁇ alkylaminosulphonyl; p and q each independently represent 0 or 1 ; Y represents a bond, oxygen, sulphur, CH 2 , C(O) or NR 9 ;
• R 7a and R 7b are both hydrogen
• R 8 represents hydrogen or C 1 -C 6 alkyl
• R 9 represents hydrogen or C 1 -C 6 alkyl
• R 10 represents hydrogen, or a saturated or unsaturated 3- to 10-membered ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, trifluoromethyl, cyano, carboxyl, hydroxyl, nitro, -S(O) r R 15 , -NR 16 S(O) 8 R 17 , -C(O)NR 18 R 19 , -NHC(O)R 20 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxycarbonyl and a saturated or unsaturated 4- to 7- membered monocyclic ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the monocyclic ring system itself being optionally substituted by
• C 1 -C 6 alkyl each independently represent O, 1 or 2;
• R 7 represents a 6- to 14-membered aromatic or heteroaromatic ring system optionally substituted by one or more substituents independently selected from halogen, trifluoromethyl, hydroxyl, carboxyl, C 1 -C 6 alkyl (optionally substituted by at least one -NR 24 R 25 ), C 1 -C 6 alkoxy (optionally substituted by at least one -NR 26 R 27 ),
• R 24 , R 25 , R 26 , R 27 , R 28 and R 29 each independently represent hydrogen or C 1 -C 6 alkyl
• R 30 represents hydrogen, C 1 -C 6 alkyl, phenyl-C 0 -C 6 alkyl or C 2 -C 6 alkylene- NR 31 R 32 ; either R 31 and R 32 each independently represent hydrogen or C 1 -C 6 alkyl, or R 31 and
• R 32 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen;
• R 33 represents hydrogen, C 1 -C 6 alkyl, phenyl-Co-C ⁇ alkyl or C 2 -C 6 alkylene-
• NR 37 R 38 represents a saturated, 5- or 6-membered nitrogen-containing ring
• R 35 and R 36 each independently represent hydrogen or Ci-C 6 alkyl; and either R 37 and R 38 each independently represent hydrogen or C 1 -C 6 alkyl, or R 37 and
• R 38 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from o nitrogen and oxygen; with the proviso that R 6 does not represent hydrogen or an unsubstituted C 1 -C 6 alkyl group; or a pharmaceutically acceptable salt thereof.
• the present invention provides a compound of formula (I) wherein s R 1 represents hydrogen; each of R 2 , R 3 , R 4 , R 5 , R 4 and R 5 independently represents hydrogen or C 1 -C 6 alkyl; e is O or 1;
• A represents CH 2 , C(O) or S(O) 2 ;
• R 6 represents a group -(XVY-(ZX-R 1 °;
• X and Z each independently represent a C 1 -C 6 alkylene group optionally substituted with at least one substituent selected from halogen, trifluoromethyl, amino (NH 2 ), (di)- 5 C 1 -C 6 alkylamino, ⁇ i)-C 1 -C 6 alkylaminocarbonyl, C 1 -C 6 alkylcarbonylamino, sulphonamido (-SO 2 NH 2 ) and (di)-CrC 6 alkylaminosulphonyl; p and q each independently represent O or 1;
• Y represents a bond, oxygen, sulphur, CH 2 , C(O) or NR 9 ;
• R 7a and R 7b are both hydrogen; 0 R 8 represents hydrogen or Cj-C 6 alkyl;
• R 9 represents hydrogen or C 1 -C 6 alkyl
• R 10 represents hydrogen, or a saturated or unsaturated 3- to 10-membered ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and. sulphur, the ring system being optionally substituted by one or more substituents independently selected from halogen, trifmoromethyl, cyano, carboxyl, hydroxyl, nitro, -S(O) 1 R 15 , -NR 16 S(O) 8 R 17 , -C(O)NR 18 R 19 , -NHC(O)R 20 , C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxycarbonyl and a saturated or unsaturated 4- to 7- membered monocyclic ring system optionally comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, the monocyclic ring system itself being optionally substituted by
• R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 23 each independently represent hydrogen or Cj-C 6 alkyl; r, s and t each independently represent 0, 1 or 2;
• R 7 represents a 6- to 14-membered aromatic or heteroaromatic ring system optionally substituted by one or more substituents independently selected from halogen, trifluoromethyl, hydroxyl, carboxyl, C 1 -C 6 alkyl (optionally substituted by at least one -NR 24 R 25 ), C 1 -C 6 alkoxy (optionally substituted by at least one -NR 26 R 27 ), C 1 -C 6 alkoxycarbonyl, -NR 28 R 29 , C 1 -C 6 alkylcarbonylamino,
• R 24 , R 25 , R 26 , R 27 , R 28 and R 29 each independently represent hydrogen or C 1 -C 6 alkyl
• R 30 represents C 1 -C 6 alkylene-NR 31 R 32 ; either R 31 and R 32 each independently represent hydrogen or Ci-C 6 alkyl, or R 31 and R 32 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen;
• R 33 represents hydrogen, C 1 -C 6 alkyl or phenyl
• R 34 represents a saturated, 5- or 6-membered nitrogen-containing ring; with the proviso that R 6 does not represent hydrogen or an unsubstituted C 1 -C 6 alkyl group; or a pharmaceutically acceptable salt thereof.
• each of R 2 , R 3 , R 4 , R 5 and, if present, R 4' and R 5' independently represents hydrogen or C 1 -C 6 , or C 1 -C 4 , or Cj-C 2 alkyl.
• R 2 and R 3 are both hydrogen and R 4 and R 5 and, if present, R 4 and R 5 are, independently hydrogen or Ci-C 6 alkyl.
• each of R 2 , R 3 , R 4 , R 5 and, if present, R 4 and R 5 represents hydrogen.
• A represents C(O).
• A represents CH 2 .
• D represents oxygen
• m is an integer 0, 1, 2 or 3, for example, 1.
• n is an integer 0, 1, 2 or 3, for example, 1.
• the present invention provides a compound of formula (I) wherein X and Z each independently represent a Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkylene group optionally substituted with at least one substituent (e.g. one, two or three substituents independently) selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifhioromethyl, amino, (di)-Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkylamino (e.g.
• substituent e.g. one, two or three substituents independently
• halogen e.g. fluorine, chlorine, bromine or iodine
• trifhioromethyl amino, (di)-Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkylamino
• the present invention provides a compound of formula (I) wherein R 6 is -X-Y-R 10 .
• the present invention provides a compound of formula (I) wherein R 6 is -X-Y-Z-R 10 .
• X represents a C 1 -C 5 alkylene group
• Z represents a Ci-C 2 alkylene group.
• p is 0 and q is 1.
• p is 1 and q is 0.
• p and q are either both 0 or 1.
• Y represents a bond, oxygen, CH 2 or NR 9 . In a further aspect of the invention Y is NR 9 .
• the present invention provides a compound of formula (I) wherein R 7a and R 7b are, independently, hydrogen, methyl or ethyl; for example R 7a and R 7b are both hydrogen.
• the present invention provides a compound of formula (I) wherein R 8 represents hydrogen or C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl.
• the present invention provides a compound of formula (I) wherein R 9 represents hydrogen or C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl.
• the present invention provides a compound of formula (I) wherein R 9 is C 1 -C 4 alkyl (for example methyl or ethyl).
• R 10 represents hydrogen, or a saturated or unsaturated 3- to 10-membered (e.g. 3-, 4-, 5-, 6-, 7-, 8-, 9- or 10-membered) ring system optionally comprising a ring heteroatom (e.g. none, one, two, three or four ring heteroatoms independently) which, when present, is selected from nitrogen, oxygen and sulphur, the ring system being unsubstituted or substituted by one or more (e.g.
• substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, cyano, carboxyl, hydroxyl, nitro, -S(O) 1 R 15 , -NR 16 S(O) 2 R 17 , -C(O)NR 18 R 19 , -NHC(O)R 20 , Ci-C 6 , or Ci-C 4 , or C 1 - C 2 alkyl, C 1 -C 6 , or Ci-C 4 , or C 1 -C 2 alkoxy, Ci-C 6 , or C 1 -C 4 , or Ci-C 2 alkylcarbonyl, C 1 - C 6 , or C 1 -C 4 , or Cj-C 2 alkoxycarbonyl and a saturated or unsaturated 4-, 5-, 6- or 7- membered monocyclic ring system optionally comprising a ring heteroatom (e.g.
• substituent e.g. one, two, three or four substituents independently
• halogen e.g. fluorine, chlorine, bromine or iodine
• saturated or unsaturated 3- to 10-membered ring systems include monocyclic rings or polycyclic (e.g. bicyclic) ring systems in which two or more rings are fused.
• Examples include one, or a combination of two or more, of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo[2.2.1]heptyl, cyclopentenyl, cyclohexenyl, phenyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, diazabicyclo[2.2.1]hept-2-yl, naphthyl, benzofuranyl, benzothienyl, benzodioxolyl, quinolinyl, oxazolyl, 2,3-dihydrobenzofuranyl, tetrahydropyranyl, pyrazolyl, pyrazinyl, thiazo
• a saturated or unsaturated 3- to 10-membered ring system is piperidinyl, pyridinyl or phenyl.
• saturated or unsaturated 4- to 7-membered monocyclic ring systems include cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, morpholinyl, furanyl, thienyl, pyrrolyl, phenyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl and tetrazolyl.
• R 10 represents hydrogen, or a saturated or unsaturated 5- or 6-membered ring system optionally comprising one or more ring heteroatoms (e.g. none, one or two ring heteroatoms) which, when present, are independently selected from nitrogen and oxygen, the ring system being unsubstituted or substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen (e.g.
• none, one, two, three or four ring heteroatoms which, when present, are independently selected from nitrogen, oxygen and sulphur, the monocyclic ring system itself being unsubstituted or substituted by one or more substituents (e.g. one, two, three or four substituents) independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, -NR 21 S(O) 2 R 22 , -NHC(O)R 23 and C 1 -C 6 , or Ci-C 4 , or C 1 -C 2 alkoxy.
• substituents e.g. one, two, three or four substituents
• halogen e.g. fluorine, chlorine, bromine or iodine
• R 10 represents hydrogen, or a saturated or unsaturated 5- or 6- membered ring system optionally comprising one or more ring heteroatom (e.g. none, one or two ring heteroatoms independently) which, when present, are independently selected from nitrogen and oxygen, the ring system being unsubstituted or substituted by one or two substituents independently selected from halogen (e.g.
• R 10 represents hydrogen, or a saturated or unsaturated 5- or 6- membered ring system comprising none, one or two ring heteroatoms which, when present, are independently selected from nitrogen and oxygen, the ring system being unsubstituted or substituted by one or two substituents independently selected from halogen (e.g.
• R 10 represents hydrogen, or a saturated or unsaturated 5- or 6-membered ring system comprising none, one or two ring heteroatoms which, when present, are independently selected from nitrogen and oxygen, the ring system being unsubstituted or substituted by one or two substituents independently selected from Ci-C 4 or C 1 -C 2 alkoxycarbonyl.
• R 10 represents hydrogen, phenyl, pyridinyl or piperidinyl ring optionally substituted by C 4 alkoxycarbonyl.
• R 10 is hydrogen
• R 10 is phenyl, pyridinyl, or a piperidinyl group optionally substituted by C 1 -C 4 alkoxycarbonyl.
• R 6 is (CH 2 ) q R 1Oa , wherein q is O, 1, 2 or 3 (for example 2); R 1Oa is phenyl, pyridyl, NR 9a R 9b or piperidinyl (optionally N-substituted by C(O)O(C 1-6 alkyl)); and R 9a and R 9b are, independently, C 1-4 alkyl (for example methyl or ethyl).
• R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 23 each independently represent hydrogen or C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl.
• R 15 , R 16 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 and R 2 each independently represent C 1 -C 6 , or Ci-C 4 , or C 1 -C 2 alkyl; and R 16 , R 18 , R 19 , R 20 , R 21 and R 23 can also be hydrogen.
• R 16 , R 18 , R 19 , R 20 , R 21 and R 23 each independently represent hydrogen or Ci-C 6 , or C 1 -C 4 , or Ci-C 2 alkyl.
• R 15 , R 17 and R 22 are, independently, Ci-C 6 , or Ci-C 4 , or C 1 -C 2 alkyl.
• R 7 represents a 5- to 14-membered (5-, 6-, 7-, 8-, 9-, 10-, H-, 12-, 13- or 14-membered) aromatic or heteroaromatic ring system optionally substituted by none, one or more (e.g. none, one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, C 1 -C 6 , or C 1 -C 4 , or Cj-C 2 alkyl (optionally substituted by none, one or more, e.g.
• halogen e.g. fluorine, chlorine, bromine or iodine
• Cj-C 2 alkyl optionally substituted by none, one or more, e.g.
• Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxy (optionally substituted by none, one or more, e.g. none,one or two, -NR 26 R 27 ), C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxycarbonyl, -NR 28 R 29 , Ci-C 6 , or Ci-C 4 , or Ci-C 2 alkylcarbonylamino, Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkylsulphonylamino, phenylsulphonylamino, -C(O)NHR 30 , -SO 2 NHR 33 , C 0 -C 6 , or C 0 -C 4 , or C 0 -C 2 alkyl-R 34 , and phenyl or 5- or 6-membered heteroaromatic ring (
• substituents independently selected from halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, hydroxyl, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl, C r C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxy and -NR 35 R 36 ).
• halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, hydroxyl, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl, C r C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxy and -NR 35 R 36 ).
• R 7 represents a 6- to 14-membered (6-, 7-, 8-, 9-, 10-, H-, 12-, 13- or 14-membered) aromatic or heteroaromatic ring system optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, Cj-C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by at least one, e.g.
• halogen e.g. fluorine, chlorine, bromine or iodine
• substituents independently selected from halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, hydroxyl, C 1 -C 6 , or C 1 -C 4 , or Ci-C 2 alkyl, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxy and -NR 35 R 36 ).
• halogen such as fluorine, chlorine, bromine or iodine, trifluoromethyl, hydroxyl, C 1 -C 6 , or C 1 -C 4 , or Ci-C 2 alkyl, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxy and -NR 35 R 36 ).
• R 7 represents a 6- to 14-membered (6-, 7-, 8-, 9-, 10-, 11-, 12-, 13- or 14-membered) aromatic or heteroaromatic ring system optionally substituted by one or more (e.g. one, two, three or four) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by at least one, e.g.
• halogen e.g. fluorine, chlorine, bromine or iodine
• Ci-C 2 alkoxy (optionally substituted by at least one, e.g. one or two, -NR 26 R 27 ), C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkoxycarbonyl, -NR 28 R 29 , C 1 -C 6 , or C 1 -C 4 , or Cj-C 2 alkylcarbonylamino, C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkylsulphonylamino, phenylsulphonylamino, -C(O)NHR 30 , -SO 2 NHR 33 and C 0 -C 6 , or C 0 -C 4 , or C 0 -C 2 alkyl- R 34 .
• R 7 represents an optionally substituted 5- to 14-membered heteroaromatic ring system
• the ring system comprises from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur.
• a substituent in R 7 represents an optionally substituted 5- to 6-membered heteroaromatic ring
• the ring comprises from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur.
• R 7 represents an optionally substituted 6- to 14-membered heteroaromatic ring system
• the ring system comprises from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur.
• a substituent in R 7 represents an optionally substituted 5- to 6-membered heteroaromatic ring
• the ring comprises from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur.
• R 7 represents an optionally substituted heteroaromatic ring system
• the ring system comprises from 1 to 4 ring heteroatoms independently selected from nitrogen, oxygen and sulphur.
• Examples of 5- to 14-membered (6- to 14-membered) aromatic or heteroaromatic ring systems that may be used, which may be monocyclic or polycyclic (e.g. bicyclic or tricyclic) in which the two or more rings are fused, include one or more (in any combination) of phenyl, naphthyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5- triazinyl, 1,2,4-triazinyl, azepinyl, oxepinyl, thiepinyl, indenyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, benzisoxazolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, quina
• 5- to 6-membered heteroaromatic rings examples include pyridinyl, triazolyl and tetrazolyl.
• R 7 represents a 5- to 10-membered (for example 6- to 10-membered) aromatic or heteroaromatic ring system optionally substituted by none, one or more (e.g. none, one or two) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by (e.g. none, one or two) -NR 24 R 25 ), C 1 -C 4 , or C 1 -C 2 alkoxy (optionally substituted by (e.g.
• R 7 represents a 6- to 10-membered aromatic or heteroaromatic ring system optionally substituted by none, one or more (e.g. none, one or two) substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), frifiuoromethyl, hydroxyl, carboxyl, C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by (e.g. none, one or two) -NR 24 R 25 ), C 1 -C 4 , or C 1 -C 2 alkoxy (optionally substituted by (e.g.
• R 7 represents a 5- to 10-membered (for example 6- to 10- membered) aromatic ring system optionally substituted by one or two substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by at least one, e.g. one or two, -NR 24 R 25 ), C 1 -C 4 , or C 1 -C 2 alkoxy (optionally substituted by at least one, e.g.
• halogen e.g. fluorine, chlorine, bromine or iodine
• R 7 represents a 6- to 10-membered aromatic ring system optionally substituted by one or two substituents independently selected from halogen (e.g. fluorine, chlorine, bromine or iodine), trifluoromethyl, hydroxyl, carboxyl, C 1 -C 4 , or C 1 -C 2 alkyl (optionally substituted by at least one, e.g. one or two, -NR 24 R 25 ), C 1 -C 4 , or C 1 -C 2 alkoxy (optionally substituted by at least one, e.g.
• R 7 represents a 5- to 10-membered (for example 6- to 10- membered) aromatic ring system optionally substituted by one or more (e.g. one, two, three or four) halogen atoms.
• R 7 is phenyl or naphthyl optionally substituted by halogen (for example fluoro, chloro or bromo), hydroxy, C 1-4 alkyl, C 1-4 alkoxy, CF 3 or OCF 3 .
• R 24 , R 25 , R 26 , R 27 , R 28 and R 29 each independently represent hydrogen or C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl. It should be understood that if there is more than one group -NR 24 R 25 , the groups may be the same as, or different from, one another. Similar comments apply if there is more than one group -NR 26 R 27 .
• R 30 represents hydrogen; C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl; phenyl-C 0 -C 6 , or C 0 -C 4 , or C o -C 2 alkyl (e.g. phenyl or benzyl); or C 1 -C 6 , C 1 -C 4 , C 1 -C 2 ,
• R and R each independently represent hydrogen or Cj-C 6 , or Ci-C 4 , or C 1 -C 2 alkyl, or R 31 and R 32 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
• R 30 represents hydrogen; C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl; phenyl-C 0 -C 6 , or C 0 -C 4 , or C 0 -C 2 alkyl (e.g. phenyl or benzyl); or C 2 -C 6 or C 2 -
• R and R each independently represent hydrogen or C 1 - C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl, or R and R together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
• R 30 represents hydrogen; Ci-C 6 , or C 1 -C 4 , or C 1 -C 2 alkylene- NR 31 R 32 and either R 31 and R 32 each independently represent hydrogen or C 1 -C 6 , or C 1 -C 4 , or Ci-C 2 alkyl, or R 31 and R 32 together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
• R 33 represents hydrogen; C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl; phenyl-C 0 -C 6 , or C 0 -C 4 , or C 0 -C 2 alkyl (e.g. phenyl or benzyl); or C 2 -C 6 or C 2 -
• C 4 alkylene-NR 37 R 38 and either R 37 and R 38 each independently represent hydrogen or C 1 - C 6 , or C 1 -C 4 , or Ci-C 2 alkyl, or R and R together with the nitrogen atom to which they are attached form a 4- to 6-membered saturated heterocyclic ring optionally comprising a further ring heteroatom selected from nitrogen and oxygen such as azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
• R 33 represents hydrogen; C 1 -C 6 , or C 1 -C 4 , or Ci-C 2 alkyl or phenyl.
• R 34 represents a saturated, 5- or 6-membered nitrogen-containing ring, e.g. a ring containing one or two ring nitrogen atoms such as hydantoin.
• R 35 and R 36 each independently represent hydrogen or C 1 -C 6 , or C 1 -C 4 , or C 1 -C 2 alkyl.
• the invention provides a compound of formula (I) wherein R 1 is hydrogen; e is 0 or 1 (for example 1);
• R 2 and R 3 are hydrogen or methyl (for example R 2 and R 3 are both hydrogen);
• R 4 and R 5 and, when present, R 4 and R 5 are all hydrogen;
• A is C(O); D is O; m is 1 or 2 (for example 1); n is 1;
• R 7a and R 7b are, independently, hydrogen or C 1-4 alkyl (for example methyl), (for example
• R 7a and R 713 are both hydrogen);
• R 7 is phenyl or naphthyl optionally substituted by halogen (for example fluoro, chloro or bromo), hydroxy, C 1-4 alkyl, C 1-4 alkoxy, CF 3 or OCF 3 ;
• R 6 is (CH 2 ) q R IOa , wherein q is 0, 1, 2 or 3 (for example 2); R 1Oa is phenyl, pyridyl, NR 9a R 9b or piperidinyl (optionally N-substituted by C(O)O(C 1-6 alkyl)); and R 9a and R 9b are, independently, C 1-4 alkyl (for example methyl or ethyl); or a pharmaceutically acceptable salt thereof.
• R 1 represents hydrogen; e is O or 1; each ofR 2 , R 3 , R 4 , R 5 , R 4' and R 5> represents hydrogen;
• A represents C(O) or CH 2 ;
• D represents oxygen;
• m is 1;
• n is 1;
• R 6 represents a group -(X) p -Y-(Z) q -R 10 ;
• X represents a C 1 -C 5 alkylene group
• Z represents a C 1 -C 2 alkylene group
• p and q each independently represent 0 or 1;
• Y represents a bond, oxygen, CH 2 or NR 9 ;
• R represents methyl or ethyl;
• R 10 represents hydrogen, phenyl, pyridinyl, or a piperidinyl group optionally substituted by C 4 alkoxycarbonyl;
• R represents a 6- to 10-membered aromatic ring system optionally substituted by one or more halogen atoms.
• R 1 represents hydrogen; e is 0 or 1; each of R 2 , R 3 , R 4 , R 5 , R 4' and R 5' represents hydrogen;
• A represents C(O);
• D represents oxygen; m is l; n is 1;
• R 6 represents a group -(X) p -Y-(Z) q -R 10 ;
• X represents a C 1 -Cs alkylene group
• Z represents a Ci-C 2 alkylene group; p and q each independently represent 0 or 1;
• Y represents a bond, oxygen, CH 2 or NR 9 ;
• R 9 represents methyl or ethyl;
• R 10 represents hydrogen, phenyl, pyridinyl, or a piperidinyl group optionally substituted by C 4 alkoxycarbonyl;
• R 7 represents a 6- to 10-membered aromatic ring system optionally substituted by one or more halogen atoms.
• An example of a compound of the invention is: tert-Butyl 4-( ⁇ (2- ⁇ [2-(4 ⁇ hydroxy-2-oxo-2,3 -dihydro- 1 ,3 -benzothiazol-7- yl)ethyl] amino ⁇ ethyl) [3-(2-phenylethoxy)propanoyl] amino ⁇ methyl)pi ⁇ eridine- 1 - carboxylate; N- ⁇ 2-[2-(4-Hydroxy-2-oxo-2,3-dihydro-benzothiazol-7-yl)-ethylamino]-ethyl ⁇ -3- phenethyloxy-iV-piperidin-4-ylmethyl-propionamide;
• the present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises,
• L 1 represents a leaving group (e.g. chlorine, bromine, iodine, methanesulfonate or p ⁇ r ⁇ -toluenesulfonate) and e, R 2 , R 3 , R 4 , R 5 , R 4' , R 5' , R 6 , R 7 , R 7a , R 7b , A, D, m and n are as defined in formula (I) but R 2 and R 3 are not both alkyl, with a compound of formula (III) or a suitable salt thereof (e.g. hydrobromide or hydrochloride salt)
• a leaving group e.g. chlorine, bromine, iodine, methanesulfonate or p ⁇ r ⁇ -toluenesulfonate
• R 1 is as defined in formula (I), in the presence of a base (e.g. potassium carbonate, triethylamine or diisopropylethylamine); or
• a base e.g. potassium carbonate, triethylamine or diisopropylethylamine
• R 1 , R 4 , R 5 , R 4' , R 5' , R 6 , R 7 , R 7a , R 7b , A, D, m and n are as defined in formula (I) with a suitable reducing agent (e.g. lithium aluminium hydride or borane tetrahydrofuran complex);
• a suitable reducing agent e.g. lithium aluminium hydride or borane tetrahydrofuran complex
• the reaction may conveniently be carried out in an organic solvent such as ⁇ N-dimethylformamide, ethanol, n-butanol or dimethyl sulfoxide, at a temperature, for example, in the range from 50 to 140 0 C.
• the reaction may conveniently be carried out in an organic solvent such as methanol, ethanol, dichloromethane, acetic acid or ⁇ f-dimethylformamide containing up to 10%w of water and acetic acid.
• reaction may conveniently be carried out in an organic solvent such as tetrahydrofuran, at a temperature, for example, in the range from 0 to 60°C.
• organic solvent such as tetrahydrofuran
• L 2 represents a leaving group (such as hydroxyl or halogen, e.g. chlorine) and m, n, D, R 7 , R 7a and R 7b are as defined in formula (II).
• the reaction is conveniently carried out in the presence of an activating reagent, for example, carbonyldiimidazole or O-(7-azabenzotriazol-l-yl)- N ⁇ y/V' ⁇ '-tetramethyluroniumhexafluorophosphate (HATU), in an organic solvent, for example, i ⁇ yV-dimethylformamide or dichloromethane, at a temperature, for example in the range from 0 to60°C.
• an activating reagent for example, carbonyldiimidazole or O-(7-azabenzotriazol-l-yl)- N ⁇ y/V' ⁇ '-tetramethyluroniumhexafluorophosphate (HATU)
• HATU i ⁇ yV-dimethylformamide or dichloromethane
• L 2 represents chlorine
• the reaction is conveniently carried out in the presence of a base, for example, triethylamine or diisopropylethylamine in an organic solvent, for example, dichloromethane or tetrahydrofuran at a temperature, for example, in the range from 0 to 25 0 C.
• a base for example, triethylamine or diisopropylethylamine
• organic solvent for example, dichloromethane or tetrahydrofuran at a temperature, for example, in the range from 0 to 25 0 C.
• Compounds of formula (I) in which A represents methylene may be prepared by contacting a corresponding compound of formula (I) in which A represents carbonyl with a reducing agent, for example, lithium aluminium hydride or borane tetrahydrofuran complex in an organic solvent, for example, tetrahydrofuran at a temperature, for example in the range
• L 3 represents a leaving group (e.g. halogen) and m, n, D, R 7 , R 7a and R 7b are as defined in formula (II).
• the reaction may be carried out in the presence of a base, for example, triethylamine or diisopropylethylamine in an organic solvent, for example, dichloromethane or tetrahydrofuran at a temperature, for example, in the range from 0 to 25 0 C.
• R 4 , R 5 , R 4' , R 5' , R 6 , R 7 , R 7a , R 7b , A, D 5 m and n are as defined in formula (IV),with an oxidising agent, for example pyridinium chloro chromate or Dess-Martin periodinane in an organic solvent, for example, dichloromethane at a temperature, for example, of 25 0 C.
• an oxidising agent for example pyridinium chloro chromate or Dess-Martin periodinane in an organic solvent, for example, dichloromethane at a temperature, for example, of 25 0 C.
• an oxidising agent for example pyridinium chloro chromate or Dess-Martin periodinane in an organic solvent, for example, dichloromethane at a temperature, for example, of 25 0 C.
• an oxidising agent for example pyridinium chloro chromate or Dess-Martin periodinane in an organic solvent, for example,
• L 4 represents a leaving group (e.g. chlorine or hydroxyl) and e, R 4 , R 5 , R 4' , R 5' , R 6 , R 7 , R 7a , R 7b , A, D, m and n are as defined in formula (V), with a compound of formula (III) or a suitable salt thereof as defined above.
• L 4 represents a leaving group (e.g. chlorine or hydroxyl) and e, R 4 , R 5 , R 4' , R 5' , R 6 , R 7 , R 7a , R 7b , A, D, m and n are as defined in formula (V), with a compound of formula (III) or a suitable salt thereof as defined above.
• reaction is conveniently carried out in the presence of a base, for example, triethylamine or diisopropylethylamine in an organic solvent, for example, dichloromethane at a temperature, for example, in the range from O to 25 0 C.
• a base for example, triethylamine or diisopropylethylamine in an organic solvent, for example, dichloromethane at a temperature, for example, in the range from O to 25 0 C.
• reaction is conveniently carried out in the presence of an activating reagent, for example, carbonyldiimidazole or O-(7-azabenzotriazol-l-yl)- iVyVyV ⁇ tetramethyluroniurnheXafluorophosphate (HATU), in an organic solvent, for example, ⁇ TV-dimethylformamide or dichloromethane, at a temperature, for example in the range from 0 to60°C.
• activating reagent for example, carbonyldiimidazole or O-(7-azabenzotriazol-l-yl)- iVyVyV ⁇ tetramethyluroniurnheXafluorophosphate (HATU)
• organic solvent for example, ⁇ TV-dimethylformamide or dichloromethane
• Compounds of formula (XIII) in which A represents sulphonyl may be prepared by reacting a compound of formula (XVI) as defined above with a compound of formula (XII) as defined above, e.g. in the presence of a base such as triethylamine or diisopropylethylamine in an organic solvent such as dichloromethane or tetrahydrofuran at a temperature, for example, in the range from O to 25°C.
• a base such as triethylamine or diisopropylethylamine
• organic solvent such as dichloromethane or tetrahydrofuran
• a reducing agent for example, sodium cyanoborohydride or sodium triacetoxyborohydride in an organic solvent, for example, methanol, ethanoL, dichloromethane or N,N- dimethylformamide containing, for example, 0-10%w water.
• the reaction could also be performed in an organic solvent, for example, ethanol, acetic acid or methanol (or a combination of either) under an atmosphere of hydrogen gas with a suitable catalyst, for example, 5-10%w palladium on carbon or platinum oxide.
• Compounds of formulae (XIV) and (XV) may be prepared by processes similar to those described for the preparation of compounds of formula (XIII).
• R' is alkyl or other suitable part of a protecting group (such as Cbz), for example using trifluoroacetic acid in a suitable solvent (for example dichloromethane) or hydrogenation over Pd/C in an alcoholic solvent.
• a protecting group such as Cbz
• a suitable solvent for example dichloromethane
• Pd/C in an alcoholic solvent.
• R 5 is OH, Cl or, together with the remainder of formula (XXI), a suitable anhydride; in a suitable solvent and, optionally, in a suitable coupling agent (such as DCC, PyBrOP or HATU).
• a suitable coupling agent such as DCC, PyBrOP or HATU
• a compound of formula (XX) can be prepared by reacting a compound of formula (XXII):
• a compound of formula (XXII) can be prepared by acetal hydrolysis of a compound of formula (XXIII):
• each R'" is, independently, C 1-6 alkyl, using, for example an acid in presence of water or another carbonyl compound (trans acetalisation with eg acetone).
• a compound of formula (XXIII) can be prepared by coupling a compound of formula (XXVI)
• L 2 is a leaving group (such as hydroxy or halogen, for example chloro) under standard literature conditions.
• a compound of formula (XXVI) can be prepared by reducing a compound of formula (XXVII):
• a compound of formula (XXVII) wherein R 6 is other than hydrogen can be prepared by reductive amination of a compound of formula (XXVHI): (XXVIlI)
• an appropriate aldehyde for example an aldehyde of formula (O)CHCH 2 - Y-(Z) q -R 10
• an appropriate aldehyde for example an aldehyde of formula (O)CHCH 2 - Y-(Z) q -R 10
• hydrogenation for example l-5bar of hydrogen using a suitable catalyst (such as Palladium on carbon) in a suitable solvent (for example ethanol) at a temperature in the range 10-50 0 C
• a suitable solvent for example ethanol
• sodium triactoxyborohydride or cyanoborohydride in a suitable solvent (such as methanol and acetic acid) at a temperature in the range 10-40 0 C.
• a compound of formula (XXVIII) can be prepared by deprotecting a compound of formula (XX3X):
• P 1 is a suitable protecting group, such as tert-butoxycarbonyl, under standard literature conditions (such as trifluoroacetic acid in dichloromethane at 10-30 0 C.
• a compound of formula (XXIX) can be prepared by coupling a compound of formula (XXX): with a compound of formula (XXXI):
• a peptide coupling agent such as DCC, EDCI or HATU
• an inert solvent for example dichloromethane
• a suitable base such as a tertiary amine, for example triethylamine or Hunig's base
• compounds of formula (I) in which R 10 represents a 3- to 10-membered ring system (e.g. piperidinyl) substituted by a C 1 -C 6 alkoxycarbonyl substituent group may be converted to the corresponding compounds in which the ring system is unsubstituted by treating the former with, for example, trifluoroacetic acid or anhydrous hydrogen chloride, in an organic solvent such as dichloromethane or 1,4-dioxane at a temperature, for example, in the range from 15 to 30 0 C.
• the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, for example an acid addition salt such as a hydrochloride (for example a dihydrochloride), hydrobromide (for example a dihydrobromide), trifluoroacetate (for example a di-trifluoroacetate), sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate or/?-toluenesulphonate.
• an acid addition salt such as a hydrochloride (for example a dihydrochloride), hydrobromide (for example a dihydrobromide), trifluoroacetate (for example a di-trifluoroacetate), sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methane
• respiratory tract obstructive diseases of the airways including: asthma, including 5 bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug-induced (including aspirin and NSAID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper-responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; 0 hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vas
• osteoarthritides associated with or including osteoarthritis/osteoarthrosis both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; osteoporosis; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal-induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythemato
• arthitides for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy
• other joint disease such as intervertebral disc degeneration or temporomandibular joint degeneration
• bone remodelling disease such as osteoporosis, Paget's disease or osteonecrosis
• polychondritits such as osteoporosis, Paget's
• skin psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic
• dermatitis 5 dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; o panniculitis;cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions;
• eyes blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic s ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial;
• gastrointestinal tract glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, and food-related allergies which may have effects remote from the gut (for example migraine, rhinitis or 0 eczema);
• abdominal hepatitis, including autoimmune, alcoholic and viral; fibrosis and cirrhosis of the liver; cholecystitis; pancreatitis, both acute and chronic;
• nephritis including interstitial and glomerulonephritis; nephrotic syndrome; cystitis including acute and chronic (interstitial) cystitis and Hunner's ulcer; s acute and chronic urethritis, prostatitis, epididymitis, oophoritis and salpingitis; vulvovaginitis; Peyronie's disease; erectile dysfunction (both male and female);
• allograft rejection acute and chronic following, for example, transplantation of kidney, heart, liver, lung, bone marrow, skin or cornea or following blood transfusion; or chronic graft versus host disease; 0 10.
• CNS Alzheimer's disease and other dementing disorders including CJD and nvCJD; amyloidosis; multiple sclerosis and other demyelinating syndromes; cerebral atherosclerosis and vasculitis; temporal arteritis; myasthenia gravis; acute and chronic pain (acute, intermittent or persistent, whether of central or peripheral origin) including visceral pain, headache, migraine, trigeminal neuralgia, atypical facial pain, joint and bone pain, pain arising from cancer and tumor invasion, neuropathic pain syndromes including diabetic, post-herpetic, and HIV-associated neuropathies; neurosarcoidosis; central and peripheral nervous system complications of malignant, infectious or autoimmune processes;
• cardiovascular atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and auto-immune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins;
• oncology treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes; and,
• gastrointestinal tract Coeliac disease, proctitis, eosinopilic gastro-enteritis, mastocytosis, Crohn's disease, ulcerative colitis, microscopic colitis, indeterminant colitis, irritable bowel disorder, irritable bowel syndrome, non-inflammatory diarrhea, food- related allergies which have effects remote from the gut, e.g., migraine, rhinitis and eczema.
• the present invention provides a compound of formula (I) or a pharmaceutically- acceptable salt thereof as hereinbefore defined for use in therapy.
• the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.
• the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
• the terms “therapeutic” and “therapeutically” should be construed accordingly.
• Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
• Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
• the invention still further provides a method of treating, or reducing the risk of, an inflammatory disease or condition (including a reversible obstructive airways disease or condition) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
• the compounds of this invention may be used in the treatment of adult respiratory distress syndrome (APvDS), pulmonary emphysema, bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), asthma and rhinitis.
• APvDS adult respiratory distress syndrome
• pulmonary emphysema pulmonary emphysema
• bronchitis bronchiectasis
• COPD chronic obstructive pulmonary disease
• asthma chronic obstructive pulmonary disease
• the daily dosage of the compound of the invention if inhaled, may be in the range from 0.05 micrograms per kilogram body weight ( ⁇ g/kg) to 100 micrograms per kilogram body weight ( ⁇ g/kg).
• the daily dosage of the compound of the invention may be in the range from 0.01 micrograms per kilogram body weight ( ⁇ g/kg) to 100 milligrams per kilogram body weight (mg/kg).
• the compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• a pharmaceutically acceptable adjuvant diluent or carrier.
• Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
• the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
• the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
• compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler ® ; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.
• HFA heptafluoroalkane
• Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation.
• the compound is desirably finely divided.
• the finely divided compound preferably has a mass median diameter of s less than 10 ⁇ m, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C 8 -C 2O fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
• a dispersant such as a C 8 -C 2O fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
• the compounds of the invention may also be administered by means of a dry powder inhaler.
• the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.
• a carrier s substance for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol.
• Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch.
• the finely divided compound may be coated by another substance.
• the powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active 0 compound.
• This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler ® in which a s dosing unit meters the desired dose which is then inhaled by the patient.
• a multidose inhaler for example, that known as the Turbuhaler ® in which a s dosing unit meters the desired dose which is then inhaled by the patient.
• the active ingredient with or without a carrier substance, is delivered to the patient.
• the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato 0 starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets.
• an adjuvant or a carrier for example, lactose, saccharose, sorbitol, mannitol
• a starch for example, potato 0 starch, corn starch or amylopectin
• a cellulose derivative for example, gelatine or polyvinylpyrrolidone
• a lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol
• the cores may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
• a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
• the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
• the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol.
• Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets.
• liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
• Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
• Such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
• the compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
• the invention therefore further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
• NSAIDs non-steroidal anti-inflammatory agents
• COX-I / COX-2 inhibitors whether applied topically or systemically
• piroxicam diclofenac
• propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen
• fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin
• selective COX-2 inhibitors such as
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma- interferons; insulin-like growth factor type I (IGF-I); interleukins (IL) including ILl to 17, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF- ⁇ ) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxyfylline.
• a cytokine or agonist or antagonist of cytokine function including agents which act on cytokine signal
• the invention relates to a combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a monoclonal antibody targeting B- Lymphocytes (such as CD20 (rituximab), MRA-aIL16R) or T-Lymphocytes (CTLA4-Ig, HuMax Il-15).
• B- Lymphocytes such as CD20 (rituximab), MRA-aIL16R) or T-Lymphocytes (CTLA4-Ig, HuMax Il-15).
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a modulator of chemokine receptor function such as an antagonist of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX 3 CRl for the C-X 3 - C family.
• a modulator of chemokine receptor function such as an antagonist of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl, CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an inhibitor of matrix metalloprotease (M[MPs) 3 i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-I), collagenase-2 (MMP-8), collagenase-3 (MMP-13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-IO), and stromelysin-3 (MMP- 11) and MMP-9 and MMP- 12, including agents such as doxycycline.
• M[MPs) 3 i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase
• MMP-I matrix metalloprotease
• MMP-8 collagenase-2
• MMP-13 collagenase-3
• MMP-3 stromelys
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a leukotriene biosynthesis inhibitor, 5 -lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N " -(5-substituted)-thiophene-2-aIkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2- cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a receptor antagonist for leukotrienes (LT) B4-. LTC4, LTD4, and LTE4.
• a receptor antagonist for leukotrienes (LT) B4-. LTC4, LTD4, and LTE4 selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG- 12525, Ro-245913, irahikast (CGP 45715A) 3 and BAY x 7195.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.
• PDE phosphodiesterase
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.
• a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.
• a proton pump inhibitor such as omeprazole
• a gastroprotective histamine type 2 receptor antagonist such as a gastroprotective histamine type 2 receptor antagonist.
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an antagonist of the histamine type 4 receptor.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.
• an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochlor
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an anticholinergic agents including muscarinic receptor (Ml 3 M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
• Ml 3 M2, and M3 antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.
• a chromone such as sodium cromoglycate or nedocromil sodium.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an agent that modulates a nuclear hormone receptor such as PPARs.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).
• an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and another systemic or topically-applied antiinflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
• another systemic or topically-applied antiinflammatory agent such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
• aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine
• immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcripta
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxyfylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.
• a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist
• ACE angiotensin-converting enzyme
• angiotensin-2 receptor antagonist angiotensin-2 receptor antagonist
• a lipid lowering agent such as a statin or a fibrate
• a modulator of blood cell morphology such as
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a comP inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide synthase), or an anti- Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.
• a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dop
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitryptiline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.
• analgesic for example an opioid or derivative thereof
• carbamazepine for example an opioid or derivative thereof
• phenytoin for example an opioid or derivative thereof
• sodium valproate for example an opioid or derivative thereof
• amitryptiline or other anti-depressant agent-s sodium valproate
• paracetamol paracetamol
• non-steroidal anti-inflammatory agent for example an opioid or derivative thereof
• the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.
• a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.
• a compound of the present invention, or a pharmaceutically acceptable salt thereof can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate.
• the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JNK, protein kinase A, B or C, or IKK), or a kinase involved in cell cycle regulation (such as a cylin dependent kinase);
• -receptor antagonist for example colchicine
• anti-gout agent for example colchicine
• xanthine oxidase inhibitor for example allopurinol
• uricosuric agent for example probenecid, sulfinpyrazone or benzbromarone
• growth hormone secretagogue for example transforming growth factor (TGF ⁇ );
• PDGF platelet-derived growth factor
• fibroblast growth factor for example basic fibroblast growth factor (bFGF);
• GM-CSF granulocyte macrophage colony stimulating factor
• capsaicin cream for example tachykinin NK.subl.
• NKP-608C SB-233412 (talnetant) or D-4418
• elastase inhibitor such as UT-77 or ZD-0892
• TACE TNF-alpha converting enzyme inhibitor
• iNOS induced nitric oxide synthase
• chemoattractant receptor-homologous molecule expressed on TH2 cells such as a CRTH2 antagonist
• inhibitor of P38 agent modulating the function of Toll-like receptors (TLR),
• agent modulating the activity of purinergic receptors such as P2X7
• inhibitor of transcription factor activation such as NFkB 5 API or STATS
• a glucocorticoid receptor GR-receptor
• the present invention provides a combination (for example for the treatment of COPD, asthma or allergic rhinitis) of a compound of formula (I) and one or more agents selected from the list comprising: o a non-steroidal glucocorticoid receptor (GR-receptor) agonist; o a PDE4 inhibitor including an inhibitor of the isoform PDE4D; o a muscarinic receptor antagonist (for example a Ml, M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine; o a modulator of chemokine receptor function (such as a CCRl receptor antagonist); or, o an inhibitor of p38 kinase function.
• GR-receptor non-steroidal glucocorticoid receptor
• PDE4 inhibitor including an inhibitor of the isoform PDE4D
• a compound of the invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an existing therapeutic agent for the. treatment of cancer, for example suitable agents include:
• an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as .
• a topoisomerase inhibitor for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin
• a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromat
• an antioestrogen for example tamoxifen, toremifene, raloxifene, droloxifene or i
• an agent which inhibits cancer cell invasion for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function
• an inhibitor of growth factor function for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbbl antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gef ⁇ tinib, AZD 1839), N-(3-ethynylphenyl)-6,7
• a growth factor antibody for example
• an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin);
• vascular endothelial growth factor for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354
• a compound that works by another mechanism for example linomide, an inhibitor of integrin ⁇ v ⁇ 3 function or an angiostatin
• a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213;
• an agent used in antisense therapy for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense;
• an agent used in a gene therapy approach for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drug resistance gene therapy; or
• an agent used in an immunotherapeutic approach for example ex- vivo and in-vivo approaches to increase the
• SCX Solid phase extraction with a sulfonic acid sorbent
• the reaction mixture was hydrogenated at 2.5 bar for 24 hours, filtered and concentrated. The residue was dissolved in methanol and passed through a SCX cartridge eluting with methanol. The product was eluted with 7N ammonia in methanol to afford the sub-titled compound (4.2 g) as an oil.
• 3-Phenethyloxypropanoic acid (0.34 g) was dissolved in dichloromethane (20 mL) and 5 treated with oxalyl chloride (0.32 g) and a drop of dimethylformamide at ambient temperature. The resultant solution was stirred at ambient temperature for 2 hours. The solution was then concentrated and azeotroped with dichloromethane (2 x 20 mL). The collected residue was dissolved in dichloromethane and added, portionwise, to a stirred solution of 2,2-diethoxy-N-phenethyl-eth ' anamine (0.41 g) and triethylamine (0.6 mL), dissolved in dichloromethane (20 mL), at ambient temperature.
• 3-Phenethyloxypropanoic acid (0.4 g) was dissolved in dichloromethane (10 mL) and treated with oxalyl chloride (0.35 g) and a drop of dimethylformamide at ambient temperature. The resultant solution was stirred at ambient temperaturefor 1 hour. The solution was then concentrated and azeotroped with dichloromethane (3 x 10 mL).
• N-Benzyl-7Y-(2-oxoethyl)-3-phenethyloxy-propanamide 0.19 g was 20 dissolved in methanol (8 mL) and treated with 7-(2-aminoethyl)-4-hydroxy-l,3-benthiazol- 2(3H)-one hydrobromide (0.14 g), sodium cyanoborohydride (0.022 g), acetic acid (5 drops) and water (20 drops) at ambient temperature. The resultant mixture was stirred at ambient temperature overnight. Ammonia (7 ⁇ in methanol, 5 drops) was then added and the mixture was concentrated.
• 3-Phenethyloxypropanoic acid (0.15 g) was dissolved in dichloromethane (4 mL) and treated with oxalyl chloride (0.13 g) and a drop of dimethylformamide at ambient temperature. The resultant solution was stirred at ambient temperature for 1 hour. The solution was then concentrated and azeotroped with dichloromethane (3 x 4 mL).
• N-(2,2-Diethoxyethyl)-3-phenethyloxy-N-(3-pyridyknethyl)propanamide (Example 5a), 0.086 g) was dissolved in anhydrous dioxane (3 mL) and treated with concentrated hydrochloric acid (0.6 mL) at ambient temperature. The resultant solution was stirred at ambient temperature for 2.5 hours. The reaction mixture was then poured into dichloromethane (10 mL) and basified with saturated sodium bicarbonate.
• 3-Phenethyloxypropanoic acid (0.25 g) was dissolved in dichloromethane (8 mL) and treated with oxalyl chloride (0.22 g) and a drop of dimethylformamide at ambient temperature. The resultant solution was stirred at ambient temperature for 1 hour. The solution was then concentrated and azeotroped with dichloromethane (3 x 8 mL).
• Oxalyl chloride (0.33 g) was added dropwise to a solution of 3-[2-(l- naphthyl)ethoxy]propanoic acid (Example 7b), 0.53 g) in dichloromethane (10 mL) 3 dimethylformamide (1 drop) was added and stirring continued at room temperature for 1 hour. The mixture was subsequently concentrated, re-dissolved in dichloromethane (10 mL) and added dropwise to a solution of 2-(2-diethylaminoethylamino)ethanol (0.35 g) and diisopropylethylamine (0.56 g) in dichloromethane (10 mL).
• Triethylamine (0.29 g) was added and the reaction allowed to warm to room temperature over 1 hour, the mixture was subsequently diluted (dichloromethane 30 mL), the organics washed with sodium bicarbonate (20 mL), brine (2OmL), dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to give the sub-titled compound (0.21 g).
• the crude residue was purified by flash column chromatography eluting with 1% ammonia; 5%-7% methanol in dichloromethane.
• the isolated product was dissolved in dichloromethane and treated with 4N hydrogen chloride in 1,4-dioxane (0.5 mL) and concentrated.
• the oily residue obtained was triturated with ether and then concentrated once the ether had been decanted to yield the titled compound as a white solid (0.089 g).
• Oxalyl chloride (0.078 g) was added dropwise to a solution of 3-phenethyloxypropanoic acid (0.10 g) in dichloromethane (10 mL), dimethyl formamide (1 drop) was added and stirring continued at room temperature for 1 hour.
• the crude aldehyde was dissolved in methanol (20 mL) and 7-(2- aminoethyl)-4-hydroxy-3H-benzothiazol-2-one hydrochloride (0.078 g) was added along with acetic acid (0.1 mL) and water (0.1 mL). After stirring at room temperature for 30 minutes, sodium cyanoborohydride (0.012 g) was added and the reaction mixture stirred overnight. Ammonia (7 ⁇ in methanol, 1 mL) was added and the mixture was concentrated.
• 3-Phenethyloxypropanoic acid (0.1 g) was dissolved in dichloromethane (3 mL) and treated with oxalyl chloride (0.09 g) and a drop of dimethylformamide at room temperature. The resultant solution was stirred at room temperature for 1.5 hours. The solution was then concentrated and azeotroped with dichloromethane (2 x 3 mL).
• the mixture was concentrated in vacuo and the residue was taken up in methanol (25 mL) and adsorbed onto silica gel.
• the adsorbed mixture was purified by flash chromatography to yield the titled compound (0.51 g) as a crystalline yellow solid.
• 3-Phenethyloxypropanoic acid (0.779 g) was dissolved in dichloromethane (10 mL) and treated with oxalyl chloride (0.69 mL). The resultant solution was stirred at room temperature for 1 hour. The solution was then concentrated and azeotroped with dichloromethane (3 x 4 mL). The residue was dissolved in dichloromethane (4 mL) and added, portionwise, to a stirred solution of tert-bntyl 4-[(2-hydroxyethyl)amino]piperidine- 1-carboxylate (Example l la), 0.95 g) and triethylamine (1.39 mL) dissolved in dichloromethane (30 mL).
• the reaction mixture was allowed to warm to room temperature over 1 hour.
• the reaction mixture was washed with saturated sodium bicarbonate solution (20 mL), then brine (2 x 20 mL), dried with anhydrous magnesium sulfate, filtered and concentrated in vacuo.
• the crude product was dissolved in • methanol (20 mL) and 7-(2-amino-ethyl)-4-hydroxy-3H-benzothiazol-2-one hydrochloride (0.27g) was added along with acetic acid (0.1 mL) and water (0.15 mL). After stirring at room temperature for 45 minutes, sodium cyanoborohydride (0.045g) was added and the reaction mixture was stirred overnight.
• Oxalyl chloride (0.23 g) was added dropwise to a solution of 3-phenethyloxypropanoic acid (0.32 g) in dichloromethane (10 niL), dimethylformamide (1 drop) was added and stirring continued at room temperature for lhour. The mixture was subsequently concentrated, redissolved in dichloromethane (10 mL) and added dropwise to a solution of 2-(2-diethylaminoethylamino)ethanol (0.26 g) and diisopropylethylamine (0.42 g) in dichloromethane (10 mL). The resulting mixture was stirred at room temperature for 1 hour, diluted (dichloromethane,. 50 mL), the organics were washed with water (2 x 20 mL), brine (20 mL), dried over magnesium sulfate and concentrated to give the crude sub-titled product (0.39 g).
• Triethylamine (0.30 g) was added and the reaction mixture was allowed to warm to room temperature over 1 hour. The mixture was subsequently diluted (dichloromethane, 30 mL), the organics washed with saturated sodium hydrogencarbonate solution (20 mL) and then brine (20 mL), dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to give a crude aldehyde product which was used immediately. The crude product was dissolved in methanol (10 mL) and 7-(2-aminoethyl)-4-hydroxy-3H-benzothiazol-2- one hydrochloride (0.15 g) added along with acetic acid (0.1 mL) and water (0.1 mL).
• N-Benzyl-iV-[2-[2-(4-hydroxy-2-oxo-3H-benzothiazol-7-yl)ethylamino]ethyl]-3- phenethyloxy-propanamide (Example 4, 0.1 g) was dissolved in tetrahydrofuran (6 mL) and treated with borane (IM in tetrahydrofuran, 1 mL) at room temperature. The resultant solution was heated at 50 0 C for 3 hours. The reaction was then cooled to 0°C and methanol (6 mL) was added dropwise. Following this, the mixture was concentrated and the collected residue was dissolved in methanol (6 mL) and treated with concentrated hydrochloric acid (1.6 mL).
• Oxalyl chloride (0.12 g) was added dropwise to a solution of 3-phenethyloxypropanoic acid (0.15 g) in dichloromethane (10 mL), dimethylfo ⁇ namide (1 drop) was added and stirring continued at room temperature for lhour. The mixture was subsequently concentrated, redissolved in dichloromethane (10 mL) and added dropwise to a solution of 2-(2-dimethylaminoethylamino)ethanol (0.10 g) and diisopropylethylamine (0.29 g) in dichloromethane (10 mL). The resulting mixture was stirred at room temperature for 1 hour and diluted (dichloromethane, 50 mL).
• Triethylamine (0.11 g) was added and the reaction mixture was allowed to warm to room temperature over a period of 1 hour. The mixture was subsequently diluted (dichloromethane, 30 mL), the organics washed with saturated sodium hydro gencarbonate solution (20 mL) and then brine (2OmL), dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to give a crude aldehyde product which was used immediately. The crude product was dissolved in methanol (10 mL) and 7-(2-aminoethyl)- 4-hydroxy-3H-benzothiazol-2-one hydrochloride (0.054 g) added along with acetic acid (0.1 mL) and water (0.1 mL).
• Example 16 iV-[2-(Diethylamino)ethyl]-iV-(2- ⁇ [2-(4-hydroxy-2-oxo-2,3-dihydro-l,3- benzothiazol-7-yl)ethyl]amino ⁇ ethyl)-3-[2-(l-naphthyI)ethoxy]propanamide dihydrobromide.
• the reaction mixture was poured into water (1.8 L) and the acidic solution ( ⁇ H5) was washed with tert. butyl methyl ether (TBME) (3x500 mL).
• TBME tert. butyl methyl ether
• the aqueous phase was basified to pH8 by the addition of solid potassium carbonate and extracted with dichloromethane (3x750 mL); the combined organic extracts were dried over magnesium sulphate and concentrated to give a dark oil.
• This was dissolved in ethanol (200 mL) and 48% aqueous hydrobromic acid (73 mL) was added.
• the solution was aged for 30 minutes then evaporated to dryness.
• the residue was triturated with ethanol (560 mL); the resultant solid was collected by filtration and dried in vacuo at 50.
• the product from part e) (260 mg, 1.0 mmol) was dissolved in DCM (10 ml) and oxalyl chloride (260 ul, 3.0 mmol) was added, followed by DMF (1 drop). The mixture was stirred for 1 hour, toluene (20 ml) was added and then evaporation afforded the acid chloride.
• the product from part c) (500 mg, 1.0 mmol) was dissolved in a mixture of DCM (10 ml) and THF (10 ml), Et 3 N (420 ⁇ l, 3 mmol) was added, followed by the acid chloride (above).
• Example 17 part c) The product from Example 17 part c) (190 mg) was reacted using the method of Example 21 part g) to give the title compound as a white solid (101 mg).
• Example 21 part f The product from Example 21 part f) was suspended in 48% aq HBr (1 ml) and heated in a microwave at 100 0 C for 30 min. The resulting solution was evaporated, azeotroped with ethanol (x2) to give a residue which solidified on standing. The solid was triturated with acetonitrile and the white solid collected by filtration which was further purified by reverse phase HPLC. The desired product fractions were evaporated in vacuo, the residue dissolved in ethanol and cone. Aq. HBr (1 ml) was added. This solution was evaporated in vacuo and the residue azeotroped with ethanol (x5). The resulting solid was triturated with ethanol and collected by filtration to give the title compound as a white solid (10 mg). MS: APCI (+ve): 545 (M+l)
• Example 29 The reaction described in Example 29 also afforded iV-(2-diethylaminoethyl)-N- ⁇ 2- [2-(4-hydroxy-2-oxo-2,3-dihydro-l,3-benzothiazol-7-yl)ethylamino]ethyl ⁇ -3-[2-(3- methoxyphenyl)ethoxy]propionamide which was isolated and purified by reverse phase HPLC and converted to its dihydrobromide salt as described in Example 29. The title compound was obtained as an orange solid (4 mg).
• Oxalyl chloride (1.04 g) was added drop-wise to a solution of 3-[2-(2- naphthyl)ethoxy]propanoic acid (Example 32b), (1 g) in dichloromethane (10 ml). Dimethylformamide (1 drop) was added and stirring continued at room temperature for 30 minutes.
• Sodium triacetoxyborohydride (303 mg) was added portion-wise, and mixture stirred for 45mins. Water (10ml) was added followed by DCM, and the layers separated. The aqueous layer was extracted with DCM (x3). The remaining aqueous layer was found to contain desired material, so this was mixed with ethanol, then evaporated to dryness re-dissolved in methanol water mix, and loaded onto a pre- washed SCX cartridge. The cartridge was washed with 1 : 1 methanol:water, then methanol, then eluted with 0.07N methanolic ammonia to give a yellow film (178mg).
• H292 cells were grown in RPM (Roswell Park Memorial Institute) medium containing, 10% (v/v) FBS (foetal bovine serum) and 2 mM L-glutamine. Cells were grown in
• Cells were harvested from the flask and passaged at a 1 in 10 dilution once per week.
• the culture media was removed, washed twice with 100 ⁇ L assay buffer and replaced with 50 ⁇ L assay buffer.
• Cells were rested at room temperature for 20 minutes after which time 25 ⁇ L of rolipram (1.2 mM made up in assay buffer containing 2.4% (v/v) dimethylsulphoxide) was added.
• Cells were incubated with rolipram for 10 minutes after which time test compounds (made up as x4 concentrated stocks in assay buffer containing 4% (v/v) dimethylsulphoxide) were added and the cells were incubated for 10 minutes at room temperature.
• Final rolipram concentration in the assay was 300 ⁇ M and final vehicle concentration was 1.6% (v/v) dimethylsulphoxide.
• the reaction was stopped by removing supernatants, washing once with 100 ⁇ L assay buffer and replacing with 50 ⁇ L lysis buffer.
• the cell monolayer was frozen at -80°C for 30 minutes (or overnight).
• the concentration of cAMP (cyclic adenosine monophosphate) in the cell lysate was determined using the AlphaScreenTM methodology.
• the frozen cell plate was thawed for 20 minutes on a plate shaker then 10 ⁇ L of the cell lysate was transferred to a 96-well white plate.
• 40 ⁇ L of mixed AlphaScreenTM detection beads containing equal volumes of donor beads (pre-incubated with biotinylated cAMP in the dark for 30 minutes) and acceptor beads, was added to each well and the plate incubated at room temperature for 10 hours in the dark.
• the AlphaScreenTM signal was measured using an En Vision spectrophotometer (Perkin-Elmer Inc.) with the recommended manufacturer's settings.
• cAMP concentrations were determined by reference to a calibration curve determined in the same experiment using standard cAMP concentrations (made up in lysis buffer in a 96- well tissure-culture-treated plate and frozen/thawed alongside the test samples) and detected using the same protocol.
• Concentration response curves for agonists were constructed to determine both the pEC 50 and Intrinsic Activity. Intrinsic Activity was expressed as a fraction relative to the maximum activity determined for formoterol in each experiment. The results obtained for a representative selection of the compounds of the Examples are shown in Table 1 below.
• H292 cells were grown in 225cm2 flasks incubator at 37 0 C, 5% CO 2 in RPMI medium containing, 10% (v/v) FBS (foetal bovine serum) and 2 mM L-glutamine.
• Adherent H292 cells were removed from tissue culture flasks by treatment with
• the culture media was removed and cells were washed twice with 100 ⁇ L assay buffer and replaced with 50 ⁇ L assay buffer (HBSS solution containing 1OmM HEPES ⁇ H7.4 and 5 mM glucose). Cells were rested at room temperature for 20 minutes after which time 25 ⁇ L of rolipram (1.2 mM made up in assay buffer containing 2.4% (v/v) dimethylsulphoxide) was added. Cells were incubated with rolipram for 10 minutes after which time test compounds were added and the cells were incubated for 60 minutes at room temperature. The final rolipram concentration in the assay was 300 ⁇ M and final vehicle concentration was 1.6% (v/v) dimethylsulphoxide. The reaction was stopped by removing supernatants, washing once with 100 ⁇ L assay buffer and replacing with 50 ⁇ L lysis buffer. The cell monolayer was frozen at -80 0 C for 30 minutes (or overnight).
• the concentration of cAMP (cyclic adenosine monophosphate) in the cell lysate was determined using AlphaScreenTM methodology. The frozen cell plate was thawed for 20 minutes on a plate shaker then 10 ⁇ L of the cell lysate was transferred to a 96-well white plate. 40 ⁇ L of mixed AlphaScreenTM detection beads pre-incubated with biotinylated cAMP, was added to each well and the plate incubated at room temperature for 10 hours in the dark. The AlphaScreenTM signal was measured using an EnVision spectrophotometer (Perkin-Elmer Inc.) with the recommended manufacturer's settings. cAMP concentrations were determined by reference to a calibration curve determined in the same experiment using standard cAMP concentrations.
• Membranes were prepared from human embryonic kidney 293 (HEK293) cells expressing recombinant human (XI D receptor. These were diluted in Assay Buffer (5OmM HEPES, ImM EDTA, 0.1% gelatin, pH 7.4) to provide a final concentration of membranes that gave a clear window between maximum and minimum specific binding.
• Assay Buffer 5OmM HEPES, ImM EDTA, 0.1% gelatin, pH 7.4
• the plates were incubated for 2 hours at room temperature and then filtered onto PEI coated GF/B filter plates, pre-soaked for 1 hour in Assay Buffer, using a 96-well plate Tomtec cell harvester. Five washes with 250 ⁇ L wash buffer (5OmM HEPES, ImM EDTA, pH 7.4) were performed at 4°C to remove unbound radioactivity. The plates were dried then sealed from underneath using Packard plate sealers and MicroScint-0 (50 ⁇ L) was added to each well. The plates were sealed (TopSeal A) and filter-bound radioactivity was measured with a scintillation counter (TopCount, Packard BioScience) using a 3-minute counting protocol.
• wash buffer 250 ⁇ L wash buffer
• MicroScint-0 50 ⁇ L
• B 0 Total specific binding was determined by subtracting the mean NSB from the mean maximum binding. NSB values were also subtracted from values from all other wells. These data were expressed as percent of B 0 .
• Compound concentration-effect curves (inhibition of [ 3 H] -prazosin binding) were determined using serial dilutions typically in the range 0.1 nM to 10 ⁇ M. Data was fitted to a four parameter logistic equation to determine the compound potency, which was expressed as pIC50 (negative log molar concentration inducing 50% inhibition of [ 3 H]-prazosin binding). Results are shown in Table 2 below.
• Membrane Preparation Membranes containing recombinant human adrenergic beta 1 receptors were obtained from Euroscreen. These were diluted in Assay Buffer (5OmM HEPES 5 ImM EDTA 5 12OmM NaCl 5 0.1% gelatin, pH 7.4) to provide a final concentration of membranes that gave a clear window between maximum and minimum specific binding.
• Assay Buffer 5OmM HEPES 5 ImM EDTA 5 12OmM NaCl 5 0.1% gelatin, pH 7.4
• Assays were performed in U-bottomed 96-well polypropylene plates. 10 ⁇ L [ 125 I]- Iodocyanopindolol (0.036 nM final concentration) and 10 ⁇ L of test compound (10x final concentration) were added to each test well. For each assay plate 8 replicates were obtained for [ 125 I]-Iodocyanopindolol binding in the presence of 10 ⁇ L vehicle (10% (v/v) DMSO in Assay Buffer; defining maximum binding) or 10 ⁇ L Propranolol (10 ⁇ M final concentration; defining non-specific binding (NSB)). Membranes were then added to achieve a final volume of 100 ⁇ L.
• the plates were incubated for 2 hours at room temperature and then filtered onto PEI coated GF/B filter plates, pre-soaked for 1 hour in Assay Buffer, using a 96-well plate Tomtec cell harvester. Five washes with 250 ⁇ L wash buffer (5OmM HEPES, ImM EDTA, 12OmM NaCl, pH 7.4) were performed at 4°C to remove unbound radioactivity. The plates were dried then sealed from underneath using Packard plate sealers and MicroScint-0 (50 ⁇ L) was added to each well. The plates were sealed (TopSeal A) and filter-bound radioactivity was measured with a scintillation counter (TopCount, Packard BioScience) using a 3-minute counting protocol.
• a scintillation counter TopCount, Packard BioScience
• Membranes containing recombinant human Dopamine Subtype D2s receptors were obtained from Perkin Elmer. These were diluted in Assay Buffer (5OmM HEPES, ImM EDTA, 12OmM NaCl, 0.1% gelatin, pH 7.4) to provide a final concentration of membranes that gave a clear window between maximum and minimum specific binding.
• Assay Buffer 5OmM HEPES, ImM EDTA, 12OmM NaCl, 0.1% gelatin, pH 7.4
• Assays were performed in U-bottomed 96-well polypropylene plates. 30 ⁇ L [ 3 H]- spiperone (0.16 nM final concentration) and 30 ⁇ L of test compound (10x final concentration) were added to each test well. For each assay plate 8 replicates were obtained for [ 3 H]-spiperone binding in the presence of 30 ⁇ L vehicle (10% (v/v) DMSO in Assay Buffer; defining maximum binding) or 30 ⁇ L Haloperidol (10 ⁇ M final concentration; defining non-specific binding (NSB)). Membranes were then added to achieve a final volume of 300 ⁇ L.
• the plates were incubated for 2 hours at room temperature and then filtered onto PEI coated GF/B filter plates, pre-soaked for 1 hour in Assay Buffer, using a 96-well plate Tomtec cell harvester. Five washes with 250 ⁇ L wash buffer (5OmM HEPES, ImM EDTA, 12OmM NaCl, pH 7.4) were performed at 4 0 C to remove unbound radioactivity. The plates were dried then sealed from underneath using Packard plate sealers and MicroScint-0 (50 ⁇ L) was added to each well. The plates were sealed (TopSeal A) and filter-bound radioactivity was measured with a scintillation counter (TopCount, Packard BioScience) using a 3-minute counting protocol.
• a scintillation counter TopCount, Packard BioScience
• B 0 Total specific binding was determined by subtracting the mean NSB from the mean maximum binding. NSB values were also subtracted from values from all other wells. These data were expressed as percent of B 0 .
• Compound concentration-effect curves (inhibition of [ 3 H]-spiperone binding) were determined using serial dilutions typically in the range 0.1 nM to 10 ⁇ M. Data was fitted to a four parameter logistic equation to determine the compound potency, which was expressed as pIC 5 o (negative log molar concentration inducing 50% inhibition of [ 3 H] -spiperone binding).
• Dunkin-Hartley guinea-pigs (between 200 g and 300 g on delivery) were supplied by a designated breeding establishment. The guinea-pigs were killed by cervical dislocation and the trachea removed. The adherent connective tissue was removed and each trachea cut into four rings. The tissue rings were then attached to an isometric transducer. The tissues were washed and a force of 1 g was applied to each ring. In all experiments a paired curve design was used. A priming dose of 1 ⁇ M methacholine was applied to the tissues. The tissues were then washed (three times, one minute between washes), the resting tension of Ig was reapplied and the tissues were allowed to rest for 1 hour to equilibrate.
• Tissues were then contracted with 1 ⁇ M methacholine and once a steady response was obtained a cumulative concentration response curve to isoprenaline (10 '9 M- 10 "5 M) was constructed.
• the tissues were then washed (three times, one minute between washes) and left to rest for an hour. At the end of the resting period the tissues were contracted with 1 ⁇ M methacholine and a p[A] 5 o concentration of test compound added. Once the tissue had reached maximum relaxation, a 30 x p[A]so concentration of test compound was added. Once the tissue response had reached a plateau, 10 ⁇ M sotalol was added to the bath to confirm that the relaxation was ⁇ 2 mediated
• E and [A] are the pharmacological effect (% relaxation) and concentration of the agonist respectively; ⁇ , ⁇ , [A] 5 o and m are the asymptote, baseline, location and slope parameters, respectively.
• the p[A]s 0 and IA of each isoprenaline curve was determined from this fit, to determine if the tissue was viable for generating an onset time for the test compounds.
• the response was calculated as % relaxation of the methacholine-induced contraction.
• the results were plotted % relaxation against time and the time taken to reach a 90% relaxation value was calculated and recorded.
• a dose solution of the test compound was prepared using a suitable dose vehicle.
• the concentration of the compound in the dose solution was assayed by diluting an aliquot to a nominal concentration of SO ⁇ g-ml "1 and calibrating against duplicate injections of a standard solution and a QC standard at this concentration.
• Compounds were administered intravenously as a bolus into a caudal vein to groups of three 250-35Og rats (approximately 1 ml -kg "1 ).
• a separate group of 2 or 3 animals were dosed by oral gavage (3 ml-kg "1 ). Delivered doses were estimated by weight loss. Food was not usually withdrawn from animals prior to dosing, although this effect was investigated if necessary.
• Blood samples (0.25ml) were taken into ImI syringes from the caudal vein, transferred to EDTA tubes and plasma was prepared by centrifugation (5 min at 13000rpm) soon after sample collection, before storage at -20 0 C. Typical sampling times were 2, 4, 8, 15, 30, 60, 120, 180, 240, 300 (min) or until the terminal tl/2 was accurately described.
• the concentration of the analyte(s) were determined in plasma by quantitative mass spectrometry.
• Standard and quality control stock solutions were prepared at a concentration lmg/ml in methanol.
• a range of standard and QC stocks produced by serial dilution were added to control rat plasma (50 ⁇ l).
• the range of concentrations covered the range of levels of analyte present in the rat samples.
• Standards, QCs and samples underwent liquid extraction using 50 ⁇ l of organic solvent and lOO ⁇ l of organic solvent containing an internal standard, chosen to closely resemble the analyte.
• the samples were then mixed by repeated inversion, stored at -2O 0 C for at least 1 h, and centrifuged at 3500 rpm in a centrifuge for 20 minutes. Aliquots (120 ⁇ l) of each sample were transferred for analysis using LC-MSMS.
• Standard and quality control samples covering the range of concentrations found in the test samples were within 25 % of the nominal concentration.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Pharmacology & Pharmacy (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Pulmonology (AREA)
• Otolaryngology (AREA)
• Epidemiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Thiazole And Isothizaole Compounds (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (13)

Applications Claiming Priority (6)

Related Child Applications (1)

Publications (1)

Family

ID=37727572

Family Applications (1)

Country Status (17)

Cited By (21)

Families Citing this family (1)

Citations (14)

Family Cites Families (70)

• 2006
  • 2006-07-28 TW TW095127717A patent/TW200738658A/zh unknown
  • 2006-08-03 WO PCT/SE2006/000927 patent/WO2007018461A1/en not_active Ceased
  • 2006-08-03 BR BRPI0614542-6A patent/BRPI0614542A2/pt not_active IP Right Cessation
  • 2006-08-03 KR KR1020087003165A patent/KR20080033372A/ko not_active Ceased
  • 2006-08-03 NZ NZ565472A patent/NZ565472A/en not_active IP Right Cessation
  • 2006-08-03 JP JP2008525958A patent/JP4522474B2/ja not_active Expired - Fee Related
  • 2006-08-03 US US12/063,322 patent/US7709511B2/en active Active
  • 2006-08-03 EP EP06769596A patent/EP1915354A4/en not_active Withdrawn
  • 2006-08-03 AU AU2006277074A patent/AU2006277074B2/en not_active Ceased
  • 2006-08-03 CA CA2618511A patent/CA2618511C/en not_active Expired - Fee Related
  • 2006-08-03 MX MX2008001664A patent/MX2008001664A/es active IP Right Grant
  • 2006-08-07 MY MYPI20063812A patent/MY145647A/en unknown
  • 2006-08-08 UY UY29732A patent/UY29732A1/es not_active Application Discontinuation
  • 2006-08-09 AR ARP060103492A patent/AR056026A1/es not_active Application Discontinuation
• 2008
  • 2008-01-17 IL IL188857A patent/IL188857A0/en unknown
  • 2008-03-06 EC EC2008008246A patent/ECSP088246A/es unknown
  • 2008-03-07 NO NO20081217A patent/NO20081217L/no not_active Application Discontinuation
• 2010
  • 2010-04-27 US US12/768,372 patent/US20100210688A1/en not_active Abandoned
  • 2010-06-03 AU AU2010202319A patent/AU2010202319B2/en not_active Ceased

Patent Citations (14)

Non-Patent Citations (7)

Also Published As

Similar Documents

Legal Events